Method for treating muscle wasting syndrome using antagonist antibodies against GDF-8

US9926368B2 · kind B2 · utility

Assignee

• Wyeth, LLC · US

Inventors

• Frank S. Walsh · Via Enrico Fermi, US
• Margaret M. Zaleska · Narberth, US
• David S. Howland · Exton, US
• Lioudmila Tchistiakova · Andover, US
• Riyez Karim · North Andover, US
• Pamela Kelley · Reading, US
• Xiang-Yang Tan · Reading, US
• Seung Poon Kwak · Ewing, US
• Menelas N. Pangalos · Pennington, US

Key dates

• Filing date: Jan 22, 2015
• Grant date: Mar 27, 2018
• Expiry date: Jul 17, 2036

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.